[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 40 of about 40
1. Hanprasertpong J, Chichareon S, Wootipoom V, Buhachat R, Tassee S, Geater A: Lack of effect of perioperative blood transfusion during radical hysterectomy with lymph node dissection on the prognosis of cervical cancer stage Ib. Asian Pac J Cancer Prev; 2007 Oct-Dec;8(4):476-80
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of effect of perioperative blood transfusion during radical hysterectomy with lymph node dissection on the prognosis of cervical cancer stage Ib.
  • The aim of this retrospective study was to analyze the effects of perioperative blood transfusion during radical hysterectomy with lymph node dissection on the prognosis of cervical cancer stage Ib.
  • [MeSH-major] Blood Transfusion. Hysterectomy. Lymph Node Excision. Perioperative Care. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / secondary. Adenocarcinoma / therapy. Adult. Carcinoma, Adenosquamous / secondary. Carcinoma, Adenosquamous / therapy. Carcinoma, Small Cell / secondary. Carcinoma, Small Cell / therapy. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / therapy. Female. Humans. Lymph Nodes. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Treatment Outcome


2. Bouda J, Boudova L, Hes O, Havir M, Tempfer C, Kohlberger P, Svoboda T, Rokyta Z, Speiser P: CD44v6 as a prognostic factor in cervical carcinoma FIGO stage IB. Anticancer Res; 2005 Jan-Feb;25(1B):617-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD44v6 as a prognostic factor in cervical carcinoma FIGO stage IB.
  • The aim of our study was to clarify whether CD44v6 evaluation can serve as a universally applicable prognostic factor in patients with FIGO stage IB cervical carcinoma.
  • A retrospective study was performed on 178 FIGO stage IB (142 IB N0, 36 IB N1) radically operated cervical carcinoma patients.
  • We found a strong correlation between CD44v6 expression and squamous cell carcinoma (SCC) (SCC vs. adenocarcinoma - p<0.001) and between CD44v6 expression and deep stromal invasion, LVSI and GOG score (p<0.05).
  • In conclusion, we demonstrated that CD44v6 expression is associated with LVSI, deep stromal invasion and SCC, but has no prognostic influence on OS and DFI in a population of 178 women with FIGO stage IB cervical carcinoma.
  • [MeSH-major] Antigens, CD44 / biosynthesis. Biomarkers, Tumor. Glycoproteins / biosynthesis. Uterine Cervical Neoplasms / blood. Uterine Cervical Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15816636.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / CD44v6 antigen; 0 / Glycoproteins
  •  go-up   go-down


3. Piver MS, Ghomi A: The twenty-first century role of Piver-Rutledge type III radical hysterectomy and FIGO stage IA, IB1, and IB2 cervical cancer in the era of robotic surgery: a personal perspective. J Gynecol Oncol; 2010 Dec 30;21(4):219-24

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The twenty-first century role of Piver-Rutledge type III radical hysterectomy and FIGO stage IA, IB1, and IB2 cervical cancer in the era of robotic surgery: a personal perspective.
  • Type III radical hysterectomy reported in 1974 by Piver, Rutledge, and Smith is considered worldwide by many as the standard surgical therapy for invasive cervical carcinoma stage IB and IIA.
  • With the increasing number of robotic surgeries being performed for early stage cervical cancer worldwide, the purpose of the paper is to present our personal perspective of the 21st century role of Piver-Rutledge type III radical hysterectomy for stage IB cervical cancer in the era of robotic surgery using the da Vinci robot.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obstet Gynecol. 1975 Nov;46(5):507-10 [1196552.001]
  • [Cites] Int J Gynaecol Obstet. 2009 May;105(2):107-8 [19342051.001]
  • [Cites] Am J Obstet Gynecol. 1992 Mar;166(3):864-5 [1532291.001]
  • [Cites] Obstet Gynecol. 2006 May;107(5):1152-61 [16648423.001]
  • [Cites] Eur J Gynaecol Oncol. 2006;27(5):531-3 [17139995.001]
  • [Cites] Eur J Gynaecol Oncol. 2007;28(2):77-82 [17479665.001]
  • [Cites] Minerva Ginecol. 2009 Jun;61(3):227-37 [19415066.001]
  • [Cites] Mt Sinai J Med. 2009 Dec;76(6):567-76 [20014423.001]
  • [Cites] Gynecol Oncol. 2010 May;117(2):260-5 [20153886.001]
  • [Cites] Int J Gynecol Cancer. 2010 Apr;20(3):438-42 [20375811.001]
  • [Cites] Lancet. 1997 Aug 23;350(9077):535-40 [9284774.001]
  • [Cites] Cancer. 1991 Jul 15;68(2):272-7 [2070325.001]
  • [Cites] J Gynecol Obstet Biol Reprod (Paris). 1990;19(5):576-8 [2145357.001]
  • [Cites] Am J Clin Oncol. 1988 Feb;11(1):21-4 [3341272.001]
  • [Cites] Obstet Gynecol. 1974 Aug;44(2):265-72 [4417035.001]
  • [Cites] Gynecol Oncol. 2007 Nov;107(2):205-10 [17692367.001]
  • [Cites] Int J Med Robot. 2007 Sep;3(3):224-8 [17924449.001]
  • [Cites] Gynecol Oncol. 2008 Feb;108(2):312-6 [18035405.001]
  • [Cites] Curr Opin Obstet Gynecol. 2008 Feb;20(1):14-9 [18197000.001]
  • [Cites] Gynecol Oncol. 2008 Apr;109(1):86-91 [18279944.001]
  • [Cites] Eur J Gynaecol Oncol. 2008;29(2):109-13 [18459541.001]
  • [Cites] Am J Obstet Gynecol. 2008 Jun;198(6):649.e1-4 [18538146.001]
  • [Cites] JSLS. 2008 Jul-Sep;12(3):227-37 [18765043.001]
  • [Cites] Am J Obstet Gynecol. 2008 Oct;199(4):357.e1-7 [18928973.001]
  • [Cites] Yonsei Med J. 2008 Dec 31;49(6):879-85 [19108008.001]
  • [Cites] Curr Opin Obstet Gynecol. 2009 Feb;21(1):25-30 [19125000.001]
  • [Cites] Gynecol Oncol. 2009 Apr;113(1):28-31 [19176237.001]
  • [Cites] Minerva Ginecol. 2009 Feb;61(1):53-5 [19204661.001]
  • [Cites] Future Oncol. 2009 Feb;5(1):23-5 [19243294.001]
  • [Cites] Am J Obstet Gynecol. 1951 Oct;62(4):854-70 [14885271.001]
  • (PMID = 21278882.001).
  • [ISSN] 2005-0399
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3026299
  • [Keywords] NOTNLM ; Cervix cancer / Robotic surgey / Type III radical hysterectomy
  •  go-up   go-down


Advertisement
4. Bair MJ, Lee PH, Chan YJ: Urologic manifestations of acute appendicitis secondary to metastatic cervical cancer. J Formos Med Assoc; 2007 Sep;106(9):784-7
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urologic manifestations of acute appendicitis secondary to metastatic cervical cancer.
  • We report a 34-year-old woman who had undergone radical hysterectomy 2 years previously for stage Ib cervical cancer.
  • Pathologic examination of the surgical specimen revealed metastatic cervical cancer in the appendix.


5. Brooks R, Kizer N, Nguyen L, Jaishuen A, Wanat K, Nugent E, Grigsby P, Allsworth JE, Rader JS: Polymorphisms in MMP9 and SIPA1 are associated with increased risk of nodal metastases in early-stage cervical cancer. Gynecol Oncol; 2010 Mar;116(3):539-43
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms in MMP9 and SIPA1 are associated with increased risk of nodal metastases in early-stage cervical cancer.
  • OBJECTIVE: Heritable polymorphisms modulate metastatic efficiency in Cancer Single nucleotide polymorphisms (SNPs) in MMP9 (rs17576) and SIPA1 (rs746429, rs931127) have been associated with nodal metastases in multiple cancers.
  • We investigated the association of these SNPs with nodal metastases in early-stage cervical cancer.
  • METHODS: Consecutive patients with stage IB cervical cancer who underwent a pelvic lymph node (LN) dissection were included.
  • In patients with stage Ib1 lesions (n=304), the G allele at both SIPA1 SNPs was associated with LN metastases (rs746429 OR 10.1, P=0.01; rs931127 OR 2.4, P=0.01).
  • CONCLUSIONS: In this case-control study, SNPs in SIPA1 varied statistically in cervical cancer patients with and without nodal metastases and in MMP9 after controlling for stage and lymphvascular space invasion.

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast Dis. 2006-2007;26:157-62 [17473374.001]
  • [Cites] BMC Med Genet. 2007;8:10 [17346338.001]
  • [Cites] Neoplasia. 2007 Nov;9(11):979-86 [18030366.001]
  • [Cites] Cancer Res. 2007 Dec 1;67(23):11202-8 [18056445.001]
  • [Cites] Am J Hum Genet. 2008 Mar;82(3):794-6; author reply 796-7 [18319078.001]
  • [Cites] J Am Soc Nephrol. 2008 May;19(5):985-91 [18256358.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2870-7 [18451255.001]
  • [Cites] Int J Oncol. 2009 Jan;34(1):117-28 [19082484.001]
  • [Cites] Hum Genet. 1999 Nov;105(5):418-23 [10598806.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6430-3 [12438229.001]
  • [Cites] Virus Res. 2002 Nov;89(2):285-93 [12445668.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):49-54 [12469122.001]
  • [Cites] Gynecol Oncol. 2003 Jun;89(3):343-53 [12798694.001]
  • [Cites] Cancer Lett. 2003 Oct 28;200(2):97-105 [14568162.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1675-86 [14996727.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7622-8 [15492291.001]
  • [Cites] Obstet Gynecol Surv. 1978 Mar;33(3):174-83 [343017.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1979 Mar;5(3):327-32 [457478.001]
  • [Cites] Gynecol Oncol. 1980 Feb;9(1):68-79 [7353803.001]
  • [Cites] Acta Radiol Oncol. 1984;23(6):455-9 [6099039.001]
  • [Cites] Cancer. 1990 May 1;65(9):1923-7 [2372764.001]
  • [Cites] J Biol Chem. 1996 Feb 23;271(8):4335-41 [8626782.001]
  • [Cites] J Biol Chem. 1997 Oct 31;272(44):28081-8 [9346962.001]
  • [Cites] J Biol Chem. 1999 Jun 25;274(26):18463-9 [10373454.001]
  • [Cites] Carcinogenesis. 2004 Dec;25(12):2519-24 [15319302.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5433-9 [16061858.001]
  • [Cites] In Vivo. 2005 Sep-Oct;19(5):943-8 [16097450.001]
  • [Cites] Clin Exp Metastasis. 2005;22(3):237-46 [16158251.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10959-69 [16322244.001]
  • [Cites] Cell Cycle. 2005 Dec;4(12):1719-21 [16294041.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9329-37 [16361632.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1251-4 [16452174.001]
  • [Cites] Breast Cancer Res. 2006;8(2):R16 [16563182.001]
  • [Cites] Am J Hum Genet. 2007 Mar;80(3):531-8 [17273975.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10214-21 [17974962.001]
  • (PMID = 19906411.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / RR023249-01; United States / NCRR NIH HHS / RR / K12 RR023249; United States / NCI NIH HHS / CA / CA95713; United States / NCRR NIH HHS / RR / UL1RR024992; United States / NCRR NIH HHS / RR / UL1 RR024992; United States / NCI NIH HHS / CA / R01 CA095713; United States / NCRR NIH HHS / RR / KL2RR024994; United States / NCATS NIH HHS / TR / UL1 TR000448; United States / NCRR NIH HHS / RR / K12 RR023249-01; United States / NCRR NIH HHS / RR / KL2 RR024994
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GTPase-Activating Proteins; 0 / Nuclear Proteins; 0 / SIPA1 protein, human; EC 3.4.24.35 / Matrix Metalloproteinase 9
  • [Other-IDs] NLM/ NIHMS158727; NLM/ PMC2822070
  •  go-up   go-down


6. Fabrini MG, Gadducci A, Perrone F, Cosio S, Laliscia C, Pasqualetti F, Grespi S, Cionini L: Clinical outcome of tailored adjuvant postoperative chemoradiotherapy in IB FIGO stage cervical cancer. Anticancer Res; 2009 Oct;29(10):4205-10
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcome of tailored adjuvant postoperative chemoradiotherapy in IB FIGO stage cervical cancer.
  • AIM: The aim of the present report is to review a mono-institutional experience of postoperative radiotherapy in selected patients with cervical cancer.
  • PATIENTS AND METHODS: Between 1999 and 2008, fifty-one patients with high-risk stage IB cervical cancer underwent tailored adjuvant postoperative radiotherapy; concurrent chemoradiotherapy was administered to patients presenting a high risk of recurrence.
  • CONCLUSION: Tailored adjuvant postoperative chemoradiotherapy is able to obtain a satisfactory clinical outcome in patients with high-risk early-stage IB cervical cancer.
  • [MeSH-major] Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19846974.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


7. Naik R, Jackson KS, Lopes A, Cross P, Henry JA: Laparoscopic assisted radical vaginal hysterectomy versus radical abdominal hysterectomy--a randomised phase II trial: perioperative outcomes and surgicopathological measurements. BJOG; 2010 May;117(6):746-51
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • POPULATION: Early stage IB cervical cancer requiring radical surgical treatment.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Hysterectomy / methods. Laparoscopy / methods. Uterine Cervical Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] BJOG. 2011 Apr;118(5):632-3; author reply 634 [21392232.001]
  • (PMID = 20236108.001).
  • [ISSN] 1471-0528
  • [Journal-full-title] BJOG : an international journal of obstetrics and gynaecology
  • [ISO-abbreviation] BJOG
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


8. Cai HB, Chen HZ, Yin HH: Randomized study of preoperative chemotherapy versus primary surgery for stage IB cervical cancer. J Obstet Gynaecol Res; 2006 Jun;32(3):315-23
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized study of preoperative chemotherapy versus primary surgery for stage IB cervical cancer.
  • AIM: To determine the most effective treatment and long-term outcome of patients with stage IB carcinoma of the cervix.
  • METHODS: From January 1999 to December 2001, 106 women with cervical cancer stage IB received neoadjuvant chemotherapy (n = 52) or primary surgery (n = 54).
  • CONCLUSION: Neoadjuvant chemotherapy can effectively eliminate the pathological risk factors and improve long-term survival in patients with locally advanced cervical cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / surgery

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16764623.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


9. Petsuksiri J, Chansilpa Y, Therasakvichya S, Suntornpong N, Thephamongkhol K, Dankulchai P, Mahasitthiwat P, Ieumwananonthachai N, Veerasarn V, Sangruchi S, Pattaranutaporn P: Treatment options in bulky stage IB cervical carcinoma. Int J Gynecol Cancer; 2008 Nov-Dec;18(6):1153-62
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment options in bulky stage IB cervical carcinoma.
  • Cervical cancer is the most common female cancer in the developing countries.
  • Treatments of bulky stage IB cervical cancer have been challenged as the local control is relatively poor compared to smaller stage I disease, whether treated by radical surgery or irradiation.
  • This study will review and compare the treatment modalities and rationales of a combination of treatment including surgery, radiation therapy, and chemotherapy for bulky stage IB cervical carcinoma.
  • [MeSH-major] Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Gynecol Cancer. 2009 Apr;19(3):480 [19407578.001]
  • (PMID = 18298563.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 61
  •  go-up   go-down


10. Manchana T, Triratanachat S, Sirisabya N, Vasuratna A, Termrungruanglert W, Tresukosol D: Prevalence and prognostic significance of COX-2 expression in stage IB cervical cancer. Gynecol Oncol; 2006 Mar;100(3):556-60
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence and prognostic significance of COX-2 expression in stage IB cervical cancer.
  • OBJECTIVES: To evaluate the prevalence of cyclooxygenase-2 (COX-2), correlation with various clinicopathologic factors and prognostic significance of COX-2 in stage IB cervical cancer patients.
  • METHODS: 89 paraffin-embedded specimens of patients with stage IB cervical cancer underwent radical hysterectomy and pelvic lymphadenectomy at King Chulalongkorn Memorial Hospital during 1 January 1997-31 December 2002 and were stained with polyclonal goat antiserum against COX-2 using immunohistochemical method.
  • RESULTS: The prevalence of positive COX-2 expression in stage IB cervical cancer in this study was 49.4%.
  • Positive COX-2 expression in cervical adenocarcinoma was higher than squamous cell carcinoma (86.7% versus 40.6%, P < 0.05) and significantly expressed when lymph node metastasis was presented (100% versus 46.4%, P < 0.05).
  • CONCLUSIONS: Strong correlation was found in cervical adenocarcinoma and lymph node metastasis.
  • However, COX-2 expression failed to demonstrate as a significant prognostic factor in stage IB cervical cancer.
  • [MeSH-major] Cyclooxygenase 2 / biosynthesis. Uterine Cervical Neoplasms / enzymology
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / enzymology. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / enzymology. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Disease-Free Survival. Female. Humans. Immunohistochemistry. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16246405.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


11. Traen K, Svane D, Kryger-Baggesen N, Bertelsen K, Mogensen O: Stage Ib cervical cancer during pregnancy: planned delay in treatment--case report. Eur J Gynaecol Oncol; 2006;27(6):615-7
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage Ib cervical cancer during pregnancy: planned delay in treatment--case report.
  • Approximately 0.05% of pregnancies are complicated with cervical cancer.
  • Treatment of this malignancy during pregnancy depends on the stage of disease and gestational age at the time of diagnosis.
  • In women with Stage IB cervical cancer immediate treatment, without regard to the pregnancy, is traditionally advocated in the first and second trimester.
  • We present a case of a Stage IB1 cervical cancer, diagnosed during a twin pregnancy, and treated with a planned delay of 19 weeks.
  • We have reviewed the literature and focused on what is known about planned delay in therapy of Stage IB cervical cancer, diagnosed before 30 weeks of gestational age.
  • [MeSH-major] Carcinoma in Situ / surgery. Carcinoma, Squamous Cell / surgery. Pregnancy Complications, Neoplastic / surgery. Uterine Cervical Neoplasms / surgery

  • Genetic Alliance. consumer health - Pregnancy.
  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17290596.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


12. Richard SD, Krivak TC, Castleberry A, Beriwal S, Kelley JL 3rd, Edwards RP, Sukumvanich P: Survival for stage IB cervical cancer with positive lymph node involvement: a comparison of completed vs. abandoned radical hysterectomy. Gynecol Oncol; 2008 Apr;109(1):43-8
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival for stage IB cervical cancer with positive lymph node involvement: a comparison of completed vs. abandoned radical hysterectomy.
  • PURPOSE: Management for stage IB cervical cancer with intraoperative positive pelvic lymph nodes (LNs) is controversial.
  • PATIENTS AND METHODS: We identified all women diagnosed with stage IB cervical carcinoma from the Surveillance, Epidemiology, and End Results database from 1988-1998.
  • RESULTS: From a cohort of 3116 women diagnosed with stage IB cervical cancer, 265 (8.7%) had positive pelvic LNs and a complete pelvic and para-aortic lymphadenectomy.
  • [MeSH-major] Hysterectomy / methods. Uterine Cervical Neoplasms / radiotherapy. Uterine Cervical Neoplasms / surgery

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18234297.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Viswanathan AN, Lee H, Hanson E, Berkowitz RS, Crum CP: Influence of margin status and radiation on recurrence after radical hysterectomy in Stage IB cervical cancer. Int J Radiat Oncol Biol Phys; 2006 Aug 1;65(5):1501-7
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of margin status and radiation on recurrence after radical hysterectomy in Stage IB cervical cancer.
  • PURPOSE: To examine the relationship between margin status and local recurrence (LR) or any recurrence after radical hysterectomy (RH) in women treated with or without radiotherapy (RT) for Stage IB cervical carcinoma.
  • The significant predictors of decreased relapse-free survival on univariate analysis were the depth of tumor invasion (hazard ratio [HR] 2.14/cm increase, p = 0.007), positive margins (HR 3.92, p = 0.02), tumor size (HR 1.3/cm increase, p = 0.02), lymphovascular invasion (HR 2.19, p = 0.03), and margin status (HR 0.002/increasing millimeter from cancer for those with close margins, p = 0.03).
  • [MeSH-major] Hysterectomy. Neoplasm Recurrence, Local. Uterine Cervical Neoplasms / radiotherapy. Uterine Cervical Neoplasms / surgery

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16750323.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Rotman M, Sedlis A, Piedmonte MR, Bundy B, Lentz SS, Muderspach LI, Zaino RJ: A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study. Int J Radiat Oncol Biol Phys; 2006 May 1;65(1):169-76
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study.
  • PURPOSE: To investigate, in a phase III randomized trial, whether postoperative external-beam irradiation to the standard pelvic field improves the recurrence-free interval and overall survival (OS) in women with Stage IB cervical cancers with negative lymph nodes and certain poor prognostic features treated by radical hysterectomy and pelvic lymphadenectomy.
  • METHODS AND MATERIALS: Eligible patients had Stage IB cervical cancer with negative lymph nodes but with 2 or more of the following features: more than one third (deep) stromal invasion, capillary lymphatic space involvement, and tumor diameter of 4 cm or more.
  • CONCLUSIONS: Pelvic radiotherapy after radical surgery significantly reduces the risk of recurrence and prolongs progression-free survival in women with Stage IB cervical cancer.
  • [MeSH-major] Neoplasm Recurrence, Local. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiotherapy. Carcinoma, Adenosquamous / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Female. Humans. Hysterectomy. Lymph Node Excision. Pelvis. Radiotherapy Dosage. Survival Analysis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16427212.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


15. Silva-Filho AL, Reis FM, Traiman P, Pedrosa MS, Miranda D, Triginelli SA: Clinicopathological features influencing pelvic lymph node metastasis and vaginal and parametrial involvement in patients with carcinoma of the cervix. Gynecol Obstet Invest; 2005;59(2):92-6
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological features influencing pelvic lymph node metastasis and vaginal and parametrial involvement in patients with carcinoma of the cervix.
  • PURPOSE: This study was undertaken to evaluate clinical and pathologic findings that predicted pelvic lymph node metastasis and parametrial and vaginal involvement in patients with stage IB carcinoma of the cervix.
  • METHODS: 71 patients with diagnosis of stage IB (FIGO) cervical cancer were prospectively studied from December 1997 to August 2002.
  • The patient's age, clinical stage (IB1 or IB2), histological classification, grade of differentiation, tumor volume, and lymphatic vascular space invasion (LVSI) were evaluated.
  • RESULTS: The clinical stage was IB1 in 51 patients (71.8%) and IB2 in 20 patients (28.2%).
  • The histological classification identified squamous cell carcinoma in 60 patients (84.5%) and adenocarcinoma in 11 patients (15.5%).
  • There was no association of age, clinical stage, histological classification, grade of differentiation or tumor volume with pelvic lymph node metastasis and vaginal and parametrial involvement.
  • CONCLUSION: The presence of LVSI is significantly associated with pelvic lymph node metastasis and vaginal and parametrial involvement in patients with stage IB cervical carcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma, Squamous Cell / secondary. Pelvic Neoplasms / secondary. Uterine Cervical Neoplasms / pathology. Vaginal Neoplasms / secondary


16. Runić S, Durbaba M, Runić R: Lymphadenectomy during radical hysterectomy for cervical cancer (stage IB 1-2, HA): state of the art. J BUON; 2005 Oct-Dec;10(4):473-81
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphadenectomy during radical hysterectomy for cervical cancer (stage IB 1-2, HA): state of the art.
  • Pelvic lymphadenectomy during radical hysterectomy in surgical candidates with cervical cancer (stage IBI-1, IIA) has become a standard method of therapy starting from mid 20th century.
  • More knowledge about the natural history, predictive and prognostic factors of disease and effectiveness of surgical and adjuvant treatments of early stage cervical carcinoma has been accumulated over the past 5 decades.
  • During the latter part of the 20th century the accumulating information base led to more conservative approaches for cancer resection in an effort to decrease the morbidity of radical surgery and to preserve the fertility if possible.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17357203.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


17. Eddy GL, Bundy BN, Creasman WT, Spirtos NM, Mannel RS, Hannigan E, O'Connor D: Treatment of ("bulky") stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: a phase III trial of the gynecologic oncology group. Gynecol Oncol; 2007 Aug;106(2):362-9
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of ("bulky") stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: a phase III trial of the gynecologic oncology group.
  • METHODS: Eligible patients were required to have bulky FIGO Stage IB cervical cancer, tumor diameter > or =4 cm, adequate bone marrow, renal and hepatic function, and performance status < or =2.
  • CONCLUSION: There is no evidence from this trial that NACT offered any additional objective benefit to patients undergoing RHPPL for suboptimal Stage IB cervical cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / surgery


18. Langebrekke A, Qvigstad E: Endometriosis entrapment of the obturator nerve after previous cervical cancer surgery. Fertil Steril; 2009 Feb;91(2):622-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometriosis entrapment of the obturator nerve after previous cervical cancer surgery.
  • A 26-year-old patient underwent pelvic lymphadenectomy and trachelectomy because of cervical cancer stage IB.
  • Examinations could not reveal metastatic cancer disease, but endometriosis surrounding the obturator nerve was discovered.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Female. Humans. Laparoscopy / adverse effects. Magnetic Resonance Imaging. Neoplasm Staging. Treatment Outcome. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / surgery

  • Genetic Alliance. consumer health - Endometriosis.
  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18439590.001).
  • [ISSN] 1556-5653
  • [Journal-full-title] Fertility and sterility
  • [ISO-abbreviation] Fertil. Steril.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Lee JM, Lee KB, Lee SK, Park CY: Pattern of lymph node metastasis and the optimal extent of pelvic lymphadenectomy in FIGO stage IB cervical cancer. J Obstet Gynaecol Res; 2007 Jun;33(3):288-93
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pattern of lymph node metastasis and the optimal extent of pelvic lymphadenectomy in FIGO stage IB cervical cancer.
  • AIM: To evaluate the distribution pattern of lymph node metastasis and to determine the optimal extent of pelvic lymphadenectomy (LA) in FIGO stage IB cervical cancer.
  • METHODS: The medical records of 187 patients with FIGO stage IB cervical cancer from March 1996 to December 2002 were reviewed retrospectively.
  • One hundred patients, who underwent type III hysterectomy with pelvic LA but did not receive any adjuvant treatment, were analyzed to evaluate whether the extent of LA affected the prognosis of FIGO stage IB cervical cancer.
  • CONCLUSION: The extent of LA should be adjusted to reduce complications and not to affect adversely the prognosis of FIGO stage IB cervical cancer patients without pathologic high-risk factors.
  • [MeSH-major] Carcinoma / pathology. Lymph Node Excision / standards. Pelvis / pathology. Uterine Cervical Neoplasms / pathology

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17578357.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


20. Bristow RE, Santillan A, Diaz-Montes TP, Gardner GJ, Giuntoli RL 2nd, Peeler ST: Prevention of adhesion formation after radical hysterectomy using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier: a cost-effectiveness analysis. Gynecol Oncol; 2007 Mar;104(3):739-46
Hazardous Substances Data Bank. HYALURONIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the cost-effectiveness of an adhesion prevention strategy compared to routine care, in which no adhesion prevention measures are taken, through a decision analysis model in the clinical setting of patients undergoing radical hysterectomy and pelvic lymphadenectomy for Stage IB cervical cancer.
  • METHODS: A decision analysis model compared two strategies to manage the risk of adhesion-related morbidity following radical hysterectomy for Stage IB cervical cancer:.
  • CONCLUSIONS: Under a conservative set of clinical and economic assumptions, an adhesion prevention strategy utilizing a HA-CMC barrier in patients undergoing radical hysterectomy for Stage IB cervical cancer is cost-effective from both the perspective of society as a whole and that of a third party payer.
  • [MeSH-major] Carboxymethylcellulose Sodium / administration & dosage. Hyaluronic Acid / administration & dosage. Hysterectomy / adverse effects. Intestinal Obstruction / prevention & control. Models, Economic. Uterine Cervical Neoplasms / surgery


21. Peedicayil A, Sathish N, Gnanamony M, John S, Viswanathan FR, Naseema PS, Abraham P: Can recurrence of cervical cancer be predicted by human papillomavirus DNA in nodes or plasma? J Low Genit Tract Dis; 2009 Apr;13(2):102-6
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can recurrence of cervical cancer be predicted by human papillomavirus DNA in nodes or plasma?
  • OBJECTIVE: To determine if human papillomavirus (HPV) DNA in pelvic lymph nodes or plasma of women with early-stage cervical cancer is a marker for recurrence.
  • MATERIALS AND METHODS: Twenty-eight women undergoing radical hysterectomy for cervical cancer stage IB had HPV DNA testing in cervical tissue, plasma, and the largest lymph nodes.
  • RESULTS: Human papillomavirus DNA was detected in cervical tumor tissue from all the women.
  • Human papillomavirus viral load in cervical biopsies significantly correlated with the viral loads in the lymph nodes (r = 0.97; p = 0).
  • [MeSH-major] Alphapapillomavirus / isolation & purification. Carcinoma / virology. DNA, Viral / isolation & purification. Lymph Nodes / virology. Uterine Cervical Neoplasms / virology. Viral Load

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19387130.001).
  • [ISSN] 1526-0976
  • [Journal-full-title] Journal of lower genital tract disease
  • [ISO-abbreviation] J Low Genit Tract Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


22. Niibe Y, Karasawa K, Mizutani K: Long-term progression-free survival of invasive uterine cervical carcinoma infected with human immunodeficiency virus: a case report. Int J Gynecol Cancer; 2005 May-Jun;15(3):558-60
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term progression-free survival of invasive uterine cervical carcinoma infected with human immunodeficiency virus: a case report.
  • We report the case of a patient with invasive uterine cervical carcinoma, who is also infected with human immunodeficiency virus.
  • This patient has had the longest progression-free survival of any with acquired immunodeficiency syndrome uterine cervical carcinoma.
  • She was found to be human immunodeficiency virus positive in February 1996 and found to have uterine cervical carcinoma stage IB in July 1996.
  • The longest progression-free survival in this case may be attributable to maintenance of the CD4 cell count from the onset of uterine cervical carcinoma to death, which meant the patient's immune system to the cancer cells worked.
  • [MeSH-major] Carcinoma / pathology. Carcinoma / virology. HIV Infections / complications. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15882186.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Mehra G, Weekes A, Vantrappen P, Visvanathan D, Jeyarajah A: Laparoscopic assisted radical vaginal hysterectomy for cervical carcinoma: morbidity and long-term follow-up. Eur J Surg Oncol; 2010 Mar;36(3):304-8
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic assisted radical vaginal hysterectomy for cervical carcinoma: morbidity and long-term follow-up.
  • OBJECTIVES: To study the feasibility, morbidity and outcome of cervical cancer patients treated with laparoscopic assisted radical vaginal hysterectomy (LARVH).
  • METHODS: The study group included 53 women with cervical cancer (stage-Ib).
  • They included women undergoing LARVH at the joint cancer-centres between 1994 and 2002.
  • [MeSH-major] Carcinoma / epidemiology. Carcinoma / surgery. Hysterectomy, Vaginal / methods. Laparoscopy / methods. Uterine Cervical Neoplasms / epidemiology. Uterine Cervical Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 19800194.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


24. Kukura V, Ciglar S, Markulin-Grgić L, Santek F, Valetić J, Zovko G, Podolski P: Postoperative radiotherapy in stage IB squamous cell cervical cancer. Eur J Gynaecol Oncol; 2007;28(3):211-3
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative radiotherapy in stage IB squamous cell cervical cancer.
  • OBJECTIVE: The purpose of the study was to evaluate postoperative whole pelvic radiation for high-risk patients with FIGO Stage IB cervical cancer.
  • METHODS: One hundred and forty-eight patients with Stage IB squamous cell carcinoma of the cervix underwent radical hysterectomy and pelvic lymphadenectomy.
  • The high-risk group included women with pelvic node metastases, with positive or close surgical margins, clinical tumor size > 4.0 cm, depth of stromal invasion > 1/3 the cervical wall, grade 3 tumor and presence of lymphovascular space involvement.
  • CONCLUSION: Five-year overall survival, locoregional and distant metastases were similar in the low-risk and high-risk groups of patients, thus emphasizing the value of whole pelvic radiation in patients with unfavorable prognostic factors in Stage IB cervical cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Uterine Cervical Neoplasms / radiotherapy. Uterine Cervical Neoplasms / surgery

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17624089.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


25. Jo H, Kang S, Kim JW, Kang GH, Park NH, Song YS, Park SY, Kang SB, Lee HP: Hypermethylation of the COX-2 gene is a potential prognostic marker for cervical cancer. J Obstet Gynaecol Res; 2007 Jun;33(3):236-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypermethylation of the COX-2 gene is a potential prognostic marker for cervical cancer.
  • AIM: The aim of the present study was to evaluate the DNA hypermethylation profiles of 14 genes known to be associated with tumor behavior and their clinical significance in cervical cancer.
  • METHOD: The clinical features of 82 patients with stage IB cervical cancer were analyzed in terms of DNA hypermethylation of 14 genes (hMLH1, p16, COX-2, CDH1, APC, DAPK, MGMT, p14, RASSF1A, RUNX3, TIMP3, FHIT, THBS1, and HLTF).
  • To further investigate an alteration in COX-2 expression by DNA hypermethylation, immunohistochemistry for COX-2 protein was performed in the cervical cancer tissues.
  • CONCLUSIONS: The present results suggest that DNA hypermethylation of the COX-2 gene may be a potential prognostic marker in early stage cervical cancer, the underlying mechanism of which is independent of gene silencing.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma / genetics. Cyclooxygenase 2 / genetics. DNA Methylation. Uterine Cervical Neoplasms / genetics


26. Ivanov S, Tiufekchieva E: [Modern treatment of early-stage cervical cancer]. Akush Ginekol (Sofiia); 2006;45(7):3-5
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Modern treatment of early-stage cervical cancer].
  • AIM: In our study we tried to summerise our and foreign experience in the area of early stages of cervical cancer treatment MATERIAL AND METHODS: We examined 500 patients with early stage cervical cancer for 10 years period (1996-2006).
  • RESULTS: We analised the following important factors when treating the early stages cervical cancers: the histopathology type of tumour, the type of the conisation, the number of the tissue sections, the resection line numbers, the LVSI and the desire of the patients to preserve fertility.
  • In stage IB cervical cancer we used the best treatment choice: radical hysterectomy with pelvic lymph node dissection.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Cervix Uteri / surgery. Uterine Cervical Neoplasms / surgery

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17489161.001).
  • [ISSN] 0324-0959
  • [Journal-full-title] Akusherstvo i ginekologii︠a︡
  • [ISO-abbreviation] Akush Ginekol (Sofiia)
  • [Language] bul
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Bulgaria
  •  go-up   go-down


27. Chen KY, Hsu CH, Kao CH, Hung GU, Chiu JS, Ho KW: Colovesical fistula in a patient with recurrent cervical cancer detected by FDG PET/CT. Clin Nucl Med; 2010 Oct;35(10):808-10
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colovesical fistula in a patient with recurrent cervical cancer detected by FDG PET/CT.
  • We report the case of a 57-year-old woman with the history of stage IB cervical cancer.
  • She was found to have a metastatic squamous cell carcinoma in sigmoid colon.
  • FDG PET/CT was then performed for whole-body cancer work-up.
  • It was concluded that recurrent cervical cancer involving urinary bladder and sigmoid colon resulted in colovesical fistula.
  • [MeSH-major] Fluorodeoxyglucose F18. Intestinal Fistula / radiography. Intestinal Fistula / radionuclide imaging. Positron-Emission Tomography. Tomography, X-Ray Computed. Uterine Cervical Neoplasms / complications

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20838294.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


28. Carballo N, González-Cortijo L, González-Martín A, Rojo A, Chiva L: Indications for adjuvant radiotherapy treatment after surgery and novel modalities for treatment. Gynecol Oncol; 2008 Sep;110(3 Suppl 2):S41-4
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Carcinoma of the uterine cervix is a frequent common cancer in women.
  • Patients diagnosed with early stage cervix cancer are managed with surgery.
  • Overall survival for stage IB (IB1-IB2) and IIA, is in the range of 80-90% at 5 years.
  • In the presence of 2 of the 3 adverse risk factors, radiotherapy reduces tumor recurrence in stage IB cervical cancer with negative lymph nodes.
  • Radiotherapy plays an important role in the management of cervical cancer.
  • [MeSH-major] Uterine Cervical Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18760712.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Yu L, Tan GS, Xiang XH, Guo WB, Li HP, Huang YH, Yang JY: [Comparison of uterine artery chemoembolization and internal iliac arterial infusion chemotherapy for the combining treatment for women with locally advanced cervical cancer]. Ai Zheng; 2009 Apr;28(4):402-7
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison of uterine artery chemoembolization and internal iliac arterial infusion chemotherapy for the combining treatment for women with locally advanced cervical cancer].
  • BACKGROUND AND OBJECTIVE: Uterine artery chemoembolization (UACE) and internal iliac arterial infusion chemotherapy (IAIC) are important methods to treat cervical cancer.
  • This study was to evaluate the curative effects of UACE and IAIC on the combining treatment for women with locally advanced cervical cancer.
  • METHODS: One hundred and seventy-five patients with locally advanced cervical cancer treated between April 1997 and November 2007 were retrospectively analyzed.
  • The UACE group was treated by bilateral uterine artery chemoembolization.
  • The effective rate for clinical stage IB cervical cancer in the UACE group was 77.8%, which was significantly higher than 41.2% in the IAIC group (P=0.037).
  • However, for clinical stage II,III cervical cancer, the effective rates between the two groups had no significant differences (P=0.137 and P=0.524).
  • Postoperative pathologic examinations showed that the negative percentages of cancer cell residue and pelvic lymph node metastasis in the UACE group were slightly higher than those in the IAIC group (17.2% and 80.6% vs. 12.9% and 79.4%, P=0.504 and P=0.861).
  • CONCLUSIONS: UACE followed by preoperative radiotherapy can more effectively reduce the tumor volume of locally advanced cervical cancer compared with IAIC.
  • But UACE does not increase the pathological complete response rate and not decrease the pelvic lymph node metastasis rate, the postoperative recurrence rate, and tumor embolus within lymphovascular space.The effect of UACE on the long-term survival of locally advanced cervical cancer needs to be further evaluated.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Chemoembolization, Therapeutic. Infusions, Intra-Arterial. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brachytherapy. Carboplatin / administration & dosage. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Hysterectomy / methods. Iliac Artery. Iridium Radioisotopes / therapeutic use. Lymphatic Metastasis. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Neoplasm, Residual. Remission Induction. Retrospective Studies. Tumor Burden. Uterine Artery. Young Adult


30. Mossa B, Mossa S, Corosu L, Marziani R: Follow-up in a long-term randomized trial with neoadjuvant chemotherapy for squamous cell cervical carcinoma. Eur J Gynaecol Oncol; 2010;31(5):497-503
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follow-up in a long-term randomized trial with neoadjuvant chemotherapy for squamous cell cervical carcinoma.
  • OBJECTIVE: To assess the role of neoadjuvant chemotherapy to achieve radical surgery in a larger number of patients with locally advanced/or bulky Stage IB cervical carcinoma.
  • We conducted a trial to determine whether neoadjuvant chemotherapy would improve disease-free survival and overall survival in Stage IB-III cervical cancer.
  • METHODS: 288 patients with squamous cell carcinoma of the uterine cervix, FIGO Stage IB-IIIB were randomized to one of the following treatments: three courses of neoadjuvant chemotherapy with cisplatin, vincristine, bleomycin (NACT arm; n = 159); conventional surgery or exclusive radiotherapy (CONV arm; n = 129).
  • There was no difference in age, FIGO stage, tumor size and lymph node involvement between the two groups (p = ns).
  • Two hundred and thirty-four patients in Stage IB-IIb (n = 129 NACT arm and n = 105 CONV arm) and 24 patients in Stage III (NACT arm) who proved to be chemosensitive underwent radical hysterectomy.
  • Six Stage III patients, non responders to chemotherapy, and 24 patients, Stage III of the CONV arm, underwent radiotherapy.
  • RESULTS: The study was performed on disease-free survival related to several prognostic factors: age, FIGO stage, tumor size, grading, parametrial involvement, lymph node status and surgical margins.
  • Statistically significant differences in the recurrence of the disease were related to FIGO stage (p < 003), grading (p < .05), parametrial involvement (p < .002) lymph node status (p < .0001) and tumor size (p <.002).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / surgery. Hysterectomy. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / surgery


31. Sieunarine K, Moxey P, Boyle DC, Ungar L, Lindsay I, Del Priore G, Smith JR: Selective vessel ligation in the pelvis: an invaluable tool in certain surgical procedures. Int J Gynecol Cancer; 2005 Sep-Oct;15(5):967-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • While developing the technique of abdominal radical trachelectomy for conservative cervical cancer management, the vascular supply of the uterus was thoroughly examined.
  • Following an abdominal radical trachelectomy for stage IB cervical carcinoma, blood supply of the body of the uterus is successfully maintained by only the two infundibulopelvic vessels (n= 34).
  • The objectives of this study were to investigate the vasculature of the infundibulopelvic and broad ligaments, to assess the contribution of the ovarian and uterine vessels to overall uterine perfusion, and to consider the clinical applications of selective pelvic vessel ligation.
  • Perfusion index (PI) and oxygen saturation (O(2)Sat) measurements using a modified probe were taken at specified intervals at the uterine cornu during ten routine benign abdominal hysterectomies to assess the contribution of the ovarian and uterine vessels to overall uterine perfusion and the concepts studied were utilized in certain gynecological procedures.
  • The ovarian/infundibulopelvic vessels course medially through the broad ligament toward the uterine cornu and consistently give off a branch to the ovary on its lateral border.
  • In addition, further vessels were noted to run laterally from the uterine cornu along the ovarian ligament to the medial aspect of the ovary.
  • PI and O(2)Sat measurements imply that the uterine and ovarian vessels contribute almost equally to uterine perfusion.
  • Clinical application by selective ligation of the pelvic vasculature has been utilized in certain gynecological procedures often prone to torrential life-threatening uterine hemorrhage.
  • Selective temporary ligation of the uterine and ovarian vessels has proven useful in the surgical management of chemoresistant gestational trophoblastic disease, in the Strassman procedure, fertility-sparing surgery in ruptured cornual ectopic pregnancies, and unrelenting postpartum hemorrhage.
  • Of the six supplying vessels (ovarian, uterine, and vaginal) to the uterus only two (ovarian or uterine or a combination thereof) are required for uterine viability.
  • [MeSH-minor] Female. Humans. Hysterectomy. Oxygen / metabolism. Oxygen / pharmacology. Uterine Cervical Neoplasms / surgery

  • Hazardous Substances Data Bank. OXYGEN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16174253.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] S88TT14065 / Oxygen
  •  go-up   go-down


32. Turan T, Yildirim BA, Tulunay G, Boran N, Kose MF: Prognostic effect of different cut-off values (20mm, 30mm and 40mm) for clinical tumor size in FIGO stage IB cervical cancer. Surg Oncol; 2010 Jun;19(2):106-13
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic effect of different cut-off values (20mm, 30mm and 40mm) for clinical tumor size in FIGO stage IB cervical cancer.
  • MATERIAL AND METHODS: Medical records of 193 patients with FIGO stage IB cervical cancer (IB1: 173, IB2: 20) undergoing radical hysterectomy were evaluated.
  • Stage, cell type, grade, parametrial invasion, presence of tumor at surgical margin and depth of stromal invasion did not affect recurrence or survival rates.
  • [MeSH-major] Adenocarcinoma / pathology. Hysterectomy / methods. Uterine Cervical Neoplasms / pathology


33. Loft A, Berthelsen AK, Roed H, Ottosen C, Lundvall L, Knudsen J, Nedergaard L, Højgaard L, Engelholm SA: The diagnostic value of PET/CT scanning in patients with cervical cancer: a prospective study. Gynecol Oncol; 2007 Jul;106(1):29-34
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The diagnostic value of PET/CT scanning in patients with cervical cancer: a prospective study.
  • OBJECTIVE: To investigate the clinical value of PET/CT as a supplement to FIGO staging in patients with cervical cancer stage >or=1B.
  • CONCLUSIONS: Whole-body FDG PET/CT scanning for newly diagnosed cervical cancer FIGO stage >or=1B has a high sensitivity and specificity, and can be a valuable supplement to the FIGO staging procedure.
  • [MeSH-major] Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / radionuclide imaging


34. Kim HS, Kim JY, Park NH, Kim K, Chung HH, Kim YB, Kim JW, Kim HJ, Song YS, Kang SB: Matched-case comparison for the efficacy of neoadjuvant chemotherapy before surgery in FIGO stage IB1-IIA cervical cancer. Gynecol Oncol; 2010 Nov;119(2):217-24
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Matched-case comparison for the efficacy of neoadjuvant chemotherapy before surgery in FIGO stage IB1-IIA cervical cancer.
  • OBJECTIVE: To evaluate whether neoadjuvant chemotherapy before surgery (NCS) is more efficient than primary surgical treatment (PST) for improving clinical outcomes in FIGO stage IB1-IIA cervical cancer.
  • RESULTS: NCS reduced more definitely intermediate- and high-risk factors than PST in stage IIA disease in spite of little difference of them in stage IB disease (large tumor size, 25% vs. 52.4%; deep stromal invasion, 57.1% vs. 82.1%; lymphovascular space invasion, 35.7% vs. 65.5%; parametrial invasion, 17.9% vs. 41.7%; p<0.05).
  • Moreover, ≥2 intermediate-risk factors were less common in NCS than PST despite no difference of the number of high-risk factors between the 2 treatments, which decreased the need of adjuvant radiotherapy in patients with stage IIA disease who received NCS (46.4% vs. 84.5%, p<0.01).
  • Although there were no differences in progression-free survival and disease recurrence between the 2 treatments, NCS led to poorer overall survival than PST in stage IIA disease with no difference of it in stage IB disease.
  • CONCLUSIONS: The efficacy between NCS and PST may be similar in FIGO stage IB cervical cancer.
  • However, NCS can lead to poor prognosis despite the reduction of intermediate-risk factors and the need of adjuvant radiotherapy in FIGO stage IIA disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / surgery


35. Park NY, Cho YL, Park IS, Lee YS: Laparoscopic pelvic anatomy of nerve-sparing radical hysterectomy. Clin Anat; 2010 Mar;23(2):186-91
MedlinePlus Health Information. consumer health - Hysterectomy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study is based on 125 patients with FIGO stage IB cervical cancer who had undergone laparoscopic nerve-sparing radical hysterectomies since 1999.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20108355.001).
  • [ISSN] 1098-2353
  • [Journal-full-title] Clinical anatomy (New York, N.Y.)
  • [ISO-abbreviation] Clin Anat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Sartori E, Tisi G, Chiudinelli F, La Face B, Franzini R, Pecorelli S: Early stage cervical cancer: adjuvant treatment in negative lymph node cases. Gynecol Oncol; 2007 Oct;107(1 Suppl 1):S170-4
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early stage cervical cancer: adjuvant treatment in negative lymph node cases.
  • OBJECTIVES: In early stage cervical carcinoma, most studies of the literature show that adjuvant radiotherapy significantly reduced local relapse; its impact on survival improvement is controversial.
  • METHODS: Four hundred fifty-four patients with stage IB-IIA carcinoma of the uterine cervix were treated with primary radical hysterectomy and pelvic lymphadenectomy.
  • CONCLUSION: Post-operative radiotherapy is controversial in node-negative pathologic stage IB cervical cancer; radical surgery alone has low morbidity, enable more accurate prediction of prognosis and may be sufficient therapy in the majority of patients with lymph node-negative early stage cervical cancer.
  • [MeSH-major] Uterine Cervical Neoplasms / radiotherapy. Uterine Cervical Neoplasms / surgery

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17765298.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Jongpipan J, Charoenkwan K: Sexual function after radical hysterectomy for early-stage cervical cancer. J Sex Med; 2007 Nov;4(6):1659-65
MedlinePlus Health Information. consumer health - Women's Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sexual function after radical hysterectomy for early-stage cervical cancer.
  • INTRODUCTION: For early-stage cervical cancer, treatment with radical surgery appears effective with excellent survival.
  • Sexual dysfunction is the leading cause of symptom-induced distress after the treatments for early-stage cervical cancer.
  • There has been no study that evaluates the effect of surgical treatments for cervical cancer on sexual function in the Eastern/Asian patients.
  • AIM: To examine the effect of radical hysterectomy on postoperative sexual function in women with early-stage cervical cancer.
  • METHODS: Thirty patients with International Federation of Gynecology and Obstetrics (FIGO) stage IB cervical cancer undergoing radical hysterectomy and pelvic lymphadenectomy at the Chiang Mai University Hospital were recruited.
  • Almost all (97%) had FIGO stage IB1 disease.
  • Squamous-cell carcinoma and adenocarcinoma were diagnosed in 83% and 17%, respectively.
  • [MeSH-minor] Adult. Chi-Square Distribution. Female. Humans. Libido. Middle Aged. Neoplasm Staging. Pain Measurement. Surveys and Questionnaires. Taiwan. Uterine Cervical Neoplasms / surgery


38. Chang SJ, Kim WY, Yoo SC, Yoon JH, Chun M, Chang KH, Ryu HS: A validation study of new risk grouping criteria for postoperative treatment in stage IB cervical cancers without high-risk factors: rethinking the Gynecologic Oncology Group criteria. Eur J Obstet Gynecol Reprod Biol; 2009 Nov;147(1):91-6
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A validation study of new risk grouping criteria for postoperative treatment in stage IB cervical cancers without high-risk factors: rethinking the Gynecologic Oncology Group criteria.
  • STUDY DESIGN: We analyzed the data of 332 patients with FIGO stage IB cervical cancer who underwent radical hysterectomy between 1994 and 2007.
  • [MeSH-major] Postoperative Care / methods. Radiotherapy, Adjuvant. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / therapy


39. Lee JM, Lee KB, Park CY: Prognostic factors predicting survival in patients with FIGO stage IB cervical cancer treated surgically. Int J Gynaecol Obstet; 2006 Aug;94(2):143-4
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors predicting survival in patients with FIGO stage IB cervical cancer treated surgically.
  • [MeSH-major] Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / mortality


40. Monk BJ, Koh WJ: What is the standard therapy for bulky stage IB cervical cancer? Int J Gynecol Cancer; 2009 Apr;19(3):480
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] What is the standard therapy for bulky stage IB cervical cancer?
  • [MeSH-major] Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / therapy

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Int J Gynecol Cancer. 2008 Nov-Dec;18(6):1153-62 [18298563.001]
  • (PMID = 19407578.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down






Advertisement